Dovitinib-RIBOTAC
Based on 1 Customer Validation
Dovitinib RIBOTAC is an RNA-targeting RIBOTAC degrader that can specifically bind to and degrade pre-miR-21. Dovitinib RIBOTAC can inhibit the metastasis of breast cancer and has anti-tumor activity.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.31%
- CAS. Nr.: 2759351-68-1
- Formel: C51H56FN9O10S
- Molecular Weight:1006.11
-
Speicherung:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
In Vitro
Dovitinib RIBOTAC (0.2-5 μM) can significantly reduce the level of mature miR-21 and inhibit the invasive ability of MDA-MB-231 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231
-
Concentration:0.2, 1 and 5 μM
-
Incubation Time:/
-
Result:Significantly reduced the level of miR-21-5p.
In Vivo
Dovitinib RIBOTAC (56 mg/kg; intraperitoneal injection; every other day; 42 days) has an ameliorative effect in a mouse model of Alport Syndrome. It can stabilize the urine albumin concentration, reduce the levels of mature and precursor miR-21 in the kidneys, and increase the PPARα protein level[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MDA-MB-231-Luc cells treated female NOD/SCID mice[1]
-
Dosage:56 mg/kg
-
Administration:Intraperitoneal injection; every other day; 30 days
-
Result:Inhibited breast cancer metastasis.
Decreased the number of lung nodules.
Significantly diminished miR-21 and pre-miR-21 expression.
Derepressed PDCD4 expression while having no effect on ERK or pERK levels.
Chemical Information
-
CAS. Nr. 2759351-68-1
-
Appearance Solid
-
Molecular Weight 1006.11
-
Formel C51H56FN9O10S
-
Color Light yellow to yellow
-
SMILES
O=C1C(C2=NC3=CC(N4CCN(CCNC(NCCOCCOCCOCCOC5=C(O)C=C(/C=C6C(C(C(OCC)=O)=C(NC7=CC=CC=C7)S/6)=O)C=C5)=O)CC4)=CC=C3N2)=C(N)C8=C(C=CC=C8F)N1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 130 mg/mL (129.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Reinheit & Dokumentation
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9939 mL | 4.9696 mL | 9.9393 mL | 24.8482 mL |
| 5 mM | 0.1988 mL | 0.9939 mL | 1.9879 mL | 4.9696 mL | |
| 10 mM | 0.0994 mL | 0.4970 mL | 0.9939 mL | 2.4848 mL | |
| 15 mM | 0.0663 mL | 0.3313 mL | 0.6626 mL | 1.6565 mL | |
| 20 mM | 0.0497 mL | 0.2485 mL | 0.4970 mL | 1.2424 mL | |
| 25 mM | 0.0398 mL | 0.1988 mL | 0.3976 mL | 0.9939 mL | |
| 30 mM | 0.0331 mL | 0.1657 mL | 0.3313 mL | 0.8283 mL | |
| 40 mM | 0.0248 mL | 0.1242 mL | 0.2485 mL | 0.6212 mL | |
| 50 mM | 0.0199 mL | 0.0994 mL | 0.1988 mL | 0.4970 mL | |
| 60 mM | 0.0166 mL | 0.0828 mL | 0.1657 mL | 0.4141 mL | |
| 80 mM | 0.0124 mL | 0.0621 mL | 0.1242 mL | 0.3106 mL | |
| 100 mM | 0.0099 mL | 0.0497 mL | 0.0994 mL | 0.2485 mL |
Dovitinib-RIBOTAC Related Classifications
HY-139682 Related Classifications
Powered by Bioz